Talk:Abcam
This is the talk page for discussing improvements to the Abcam article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to multiple WikiProjects. | ||||||||||||||||||||||||||||
|
The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
Lead para
[edit]Everything I can find about this co suggests they're a (or even the) major supplier of materials and reagents to life-sciences researchers worldwide. The lead para makes them sound more like a social-media company. Which is correct?
This is what investing.com says about them, or more likely what they say about themselves.
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways. The Company is engaged in data sharing and ecommerce in the life sciences. The Company focuses on helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use its affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. It has approximately 10 locations located in the world, through life science research hubs, enabling local services and multi-language support
Compare this with the page lead!
Chrismorey (talk) 08:15, 5 November 2017 (UTC)
Edit request
[edit]This edit request by an editor with a conflict of interest was declined. Per WP:CLOSEPARAPHRASE; WP:CITEVAR. |
Hello, I'm Patrick and work at Abcam. We'd like to make some changes to this page as it is now quite out of date and is missing and/or showing false information. In line with community guidelines, please see our requests below with references.
Extended content
|
---|
About Our "about section" and bio is quite out of date and doesn't truly reflect the business as it stands. Information to be added or removed: Abcam has over 1,100 employees; Explanation of issue: our employee number is incorrect; References supporting change: [1] Information to be added or removed: Abcam is a global supplier of research tools for the life sciences industry; Explanation of issue: our current description doesn't properly fit the business; References supporting change: [2] Information to be added or removed: Abcam provides validated antibodies, reagents, and other tools to life science researchers which are essential in a wide range of fields including drug discovery, diagnostics and basic research; Explanation of issue: the areas we work in have expanded and the page does not address this; References supporting change: [3] Acquisitions As with any publicly traded company, these are important to investors and the market. Information to be added or removed: Firefly is now known as FirePlex; Explanation of issue: this product has had a name change; References supporting change: [4] Information to be added or removed: Abcam acquired Calico Biolabs in January 2019. Calico Biolabs is a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies; Explanation of issue: this acquisition is not included on the page; References supporting change: [5] Partnerships These partnerships are important for investors and the life science community. Information to be added or removed: Abcam collaborates with Molecular Devices to develop screening tools for the life sciences industry; Explanation of issue: this recent partnership is not referenced on the page; References supporting change: [6] Information to be added or removed: Abcam Merck collaboration produces new PD-L1 antibody for Immuno-oncology research; Explanation of issue: this partnership is not referenced on the page; References supporting change: [7] Information to be added or removed: Abcam and the Lou Lou Foundation collaborate to discover new tools to advance research for the development of therapeutics for CKL15 deficiency disorder; Explanation of issue: this partnership is not referenced on the page; References supporting change: [8] Information to be added or removed: Abcam collaborates with Visikol to develop new tools for improved tissue clearing and 3D imaging; Explanation of issue: this partnership is not referenced on the page; References supporting change: [9] Information to be added or removed: NanoString and Abcam enter commercial partnership to provide expanded menu of antibodies for GeoMx Digital Spatial Profiler; Explanation of issue: this partnership is not referenced on the page; References supporting change: [10] Validation standards These practices are very important to the life science community and there are a couple of important updates we've made that are not referenced on the page. Information to be added or removed: In 2015, Abcam introduced knockout validation to address the industry need for higher quality antibodies; Explanation of issue: our standards have changed quite a bit in the time since this page was last updated, and this area is very important for the market and life science community; References supporting change: [11] Financials Since we are a publicly traded company it is vital that the market and the community are up to date with our financial results. The data on our page is very out of date. Information to be added or removed: Abcam’s revenue in 2018 was £233.2m; Explanation of issue: our revenue is incredibly out of date on here, but we publish our results every year; References supporting change: [12] Information to be added or removed: Abcam’s net income in 2018 was £62.2m; Explanation of issue: our net income is also out of date; References supporting change: [13] References
|
Abcamofficial (talk) 09:01, 2 September 2019 (UTC)
Reply 02-SEP-2019
[edit] Edit request declined
Your edit request was declined for two reasons:
- Text in the request was found to be insufficiently paraphrased from the source material. Submitted text ought to be written using an editor's own words and phrases.
- The citation style used in the edit request consists of bare URL's.[a] The citation style predominantly used by the Abcam article is Citation Style 1 (CS1). Any requested edit of yours which may be implemented will need to resemble the current style already in use in the article — in this case, CS1.[b]
In the extended section below titled Citation style, I have illustrated two examples: one showing how the edit request was submitted, and another showing how requests should be submitted in the future:
Citation style
|
---|
In the example above there are three URL's provided with the claim statements, but these URL's have not been placed using Citation Style 1, which is the style predominantly used by the Abcam article. Using this style, the WikiFormatted text should resemble the following:
In the example above the references have been formatted according to Citation Style 1, which shows the author, the source's name, date, etc., all information which is lost when only the links are provided. As Wikipedia is a volunteer project, edit requests such yours are generally expected to have this formatting done before the request is submitted for review. Notes
References
|
Kindly resubmit the edit request below at your earliest convenience, taking care to ensure that it makes use of CS1 and contains words and phrases of your own making. If you have any questions about this formatting please don't hesitate to ask myself or another editor. Regards, Spintendo 11:25, 2 September 2019 (UTC)
Request edit
[edit]This edit request by an editor with a conflict of interest has now been answered. |
Hello, it's Patrick again! Thanks so much for your feedback. I've had to create a new profile as the old one conflicted with wiki's rules. I've added CS1 referencing, however some the references did not have authors listed. I've also changed the paraphrasing from the sources as much as I could - it was quite hard to do this for some of the information (like a product name change or an acquisition or financial results), but I did what I could! he collaborations section was quite challenging. Do let me know if there's a way I can do this better. Hope this looks better so we can update the page. Thanks!
Extended content
|
---|
About Our "about section" and bio is quite out of date and doesn't truly reflect the business as it stands. Information to be added or removed: Abcam has over 1,100 employees; Explanation of issue: our employee number is incorrect; References supporting change: [1] Information to be added or removed: Abcam is a producer, distributor and seller of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery; Explanation of issue: our current description doesn't properly fit the business; References supporting change: [2] Acquisitions As with any publicly traded company, these are important to investors and the market. Information to be added or removed: Firefly is now known as FirePlex; Explanation of issue: this product has had a name change; References supporting change: [3] Information to be added or removed: Abcam acquired Calico Biolabs in January 2019. Calico Biolabs is a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies; Explanation of issue: this acquisition is not included on the page; References supporting change: [4] Partnerships These partnerships are important for investors and the life science community. Information to be added or removed: Abcam collaborated with Molecular Devices, supplier of bioanalytical measurement systems, to develop new high-sensitivity fluorescent enzyme-linked immunosorbent assay (ELISA) kits; Explanation of issue: this recent partnership is not referenced on the page; References supporting change: [5] Information to be added or removed: Abcam Merck collaboration produces new PD-L1 antibody for Immuno-oncology research; Explanation of issue: this partnership is not referenced on the page; References supporting change: [6] Information to be added or removed: Abcam and the Lou Lou Foundation collaborate to discover new tools to advance research for the development of therapeutics for CKL15 deficiency disorder; Explanation of issue: this partnership is not referenced on the page; References supporting change: [7] Information to be added or removed: Abcam collaborates with Visikol to develop new tools for improved tissue clearing and 3D imaging; Explanation of issue: this partnership is not referenced on the page; References supporting change: [8] Information to be added or removed: NanoString and Abcam enter commercial partnership to provide expanded menu of antibodies for GeoMx Digital Spatial Profiler; Explanation of issue: this partnership is not referenced on the page; References supporting change: [9] Validation standards These practices are very important to the life science community and there are a couple of important updates we've made that are not referenced on the page. Information to be added or removed: In 2015, Abcam introduced knockout (KO) validation to serve the critical industry need for specific and consistent antibodies; Explanation of issue: our standards have changed quite a bit in the time since this page was last updated, and this area is very important for the market and life science community; References supporting change: [10] Financials Since we are a publicly traded company it is vital that the market and the community are up to date with our financial results. The data on our page is very out of date. This is primarily for the right hand company bio box that shows them. Information to be added or removed: Abcam’s revenue in 2018 was £233.2m; Explanation of issue: our revenue is incredibly out of date on here, but we publish our results every year; References supporting change: [11] Information to be added or removed: Abcam’s net income in 2018 was £62.2m; Explanation of issue: our net income is also out of date; References supporting change: [12] References
|
Patrickfromabcam (talk) 08:57, 16 September 2019 (UTC)
Reply 2-OCT-2019
[edit]- Thank you for providing the properly formatted references, it's much appreciated.
- To expedite your request, please provide the following information:
- Please state each specific desired change in the form of verbatim statements which can then be added to the article (if approved) by the reviewer.
- The exact location where the desired claims are to be placed should be given.
- Exact, verbatim descriptions of any text or references to be removed should also be given.[1]
- Reasons should be provided for each change (Please note: These have already been provided by the COI editor).
- In the section of text below titled Sample edit request, the four required items are shown as an example:
Sample edit request
|
---|
Notes
References
|
- Kindly open a new edit request at your earliest convenience when ready to proceed with the two needed items missing from the request (the verbatim text of additions and deletions).[a] Thank you!
Regards, Spintendo 16:36, 2 October 2019 (UTC)
Notes
- ^ In the case of the About and Validation standards sections, it appears that verbatim text has been provided. However, in the Partnerships and Acquisitions sections, the verbatim text has not been provided (i.e.,
"Abcam Merck collaboration produces new PD-L1 antibody for Immuno-oncology research"
and"Firefly is now known as FirePlex"
which both read like announcements, when the text should ideally be placed as prose).
Request edit
[edit]Part of an edit requested by an editor with a conflict of interest has been implemented. Please see the reply section below for additional information about your request. |
Thanks for responding! OK, I’ve amended the request below to suit your recommendations.
Extended content
|
---|
Change of first line summary. Location: under page header, first lines of paragraph copy on the entire page. Please remove “Abcam is a life-science e-commerce company which facilitates public customer feedback on products using reviews and ratings submitted by customers. Since 2011, through acquisition, the company has moved into direct production of biotechnological products.[2]” and replace with “Abcam is a producer, distributor and seller of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery. In 2015, Abcam introduced knockout validation to address the industry need for higher quality antibodies” [1] and [2] Change of net income section in right hand side bio box. Thank you for changing the employee number and revenue number, but the net income section still needs changing. Please remove "£49.6m (2015)[1]" and add £62.2m (2019) [3] These changes are to be made in the Acquisitions section. Information to be added: After the Firefly section (starts On 20 January, Abcam announced the acquisition of Firefly...) please add "Firefly was rebranded to FirePlex in 2016."; Explanation of issue: this product has had a name change; References supporting change: [4] Information to be added: Underneath as a new paragraph after the AxioMx section within the Acquisitions section, please add "Abcam acquired Calico Biolabs in January 2019. Calico Biolabs is a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies; Explanation of issue: this acquisition is not included on the page; References supporting change: [5] Addition of partnerships. Nothing to remove here, but can we have a new section underneath the Acquisitions section titled Partnerships. Then list out the following sentences in the same style as the Acquisitions section, as individual statements. Information to be added: Abcam collaborated with Molecular Devices, supplier of bioanalytical measurement systems, to develop new high-sensitivity fluorescent enzyme-linked immunosorbent assay (ELISA) kits; Explanation of issue: this recent partnership is not referenced on the page; References supporting change: [6] Information to be added: Abcam Merck collaboration produces new PD-L1 antibody for Immuno-oncology research; Explanation of issue: this partnership is not referenced on the page; References supporting change: [7] Information to be added: Abcam and the Lou Lou Foundation collaborate to discover new tools to advance research for the development of therapeutics for CKL15 deficiency disorder; Explanation of issue: this partnership is not referenced on the page; References supporting change: [8] Information to be added or removed: Abcam collaborates with Visikol to develop new tools for improved tissue clearing and 3D imaging; Explanation of issue: this partnership is not referenced on the page; References supporting change: [9] Information to be added: NanoString and Abcam enter commercial partnership to provide expanded menu of antibodies for GeoMx Digital Spatial Profiler; Explanation of issue: this partnership is not referenced on the page; References supporting change: [10] References
|
I hope these changes are ok for you.
Patrickfromabcam (talk) 10:06, 3 October 2019 (UTC)
Reply 3-OCT-2019
[edit]Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Spintendo 14:39, 3 October 2019 (UTC)
Proposal review 3-OCT-2019
|
---|
|
Request edit
[edit]This edit request by an editor with a conflict of interest has now been answered. |
I really appreciate the changes you've made! Thank you for the advice around other areas of it. Please see below some changes for the page, hopefully in line with the feedback you gave.
Extended content
|
---|
Change of first line summary. Location: under page header, first lines of paragraph copy on the entire page. Please remove “Abcam is a life-science e-commerce company which facilitates public customer feedback on products using reviews and ratings submitted by customers. Since 2011, through acquisition, the company has moved into direct production of biotechnological products.[2]” and replace with “Abcam is a producer, distributor and seller of protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level in a wide range of fields including drug discovery.” [1] and [2] Change of net income section in right hand side bio box. Thank you for changing the employee number and revenue number, but the net income section date still needs changing. Please remove "2015" and add "2018" [3] I try to rework the partnerships part so it is less 'statementy'. Thanks so much! References
|
Patrickfromabcam (talk) 14:03, 4 October 2019 (UTC)
Reply 8-OCT-2019
[edit]Edit request implemented Spintendo 13:24, 8 October 2019 (UTC)
- Start-Class company articles
- Low-importance company articles
- WikiProject Companies articles
- Start-Class England-related articles
- Low-importance England-related articles
- WikiProject England pages
- Talk pages of subject pages with paid contributions
- Declined requested edits
- Implemented requested edits
- Partially implemented requested edits